Corresponding Author: Adam S. Lauring, MD, PhD, Division of Infectious Diseases, Department of Internal Medicine and Department of Microbiology and Immunology, University of Michigan, 1150 W Medical Center Dr, MSRB1 5510B, Ann Arbor, MI 48109-5680 (firstname.lastname@example.org).
Published Online: January 6, 2021. doi:10.1001/jama.2020.27124
Correction: This article was corrected on February 15, 2021, to fix the heading “Spike N453Y and Mink” to the correct substitution of Y453F.
Conflict of Interest Disclosures: Dr Lauring reported receiving personal fees from Sanofi as a consultant on oseltamivir and influenza and personal fees from Roche as a member of a steering committee for a clinical trial of baloxavir and influenza, outside the submitted work. No other disclosures were reported.
B , Fischer
WM , Gnanakaran
et al; Sheffield COVID-19 Genomics Group. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell
. 2020;182(4):812-827.e19. doi:10.1016/j.cell.2020.06.043
E , Hill
V , McCrone
et al; COG-UK Consortium. Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity. Cell
. 2020;S0092867420315373.PubMedGoogle Scholar
NG , Barnard
RC , Jarvis
et al Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England. CMMID.
Preprint published online December 23, 2020. Updated December 31, 2020. doi:10.1101/2020.12.24.20248822
D , Alameh
M-G , de Silva
et al. D614G spike mutation increases SARS CoV-2 susceptibility to neutralization. Cell Host Microbe
. 2020;S193131282030634X.PubMedGoogle Scholar